Rosiglitazone and metformin vs CYP2C8 Substrates (High risk)

Interacting Drugs
Rosiglitazone and metformin
vs
CYP2C8 Substrates (High risk)
Security Level
Minor, Monitor Therapy
Mechanism
CYP2C8 Substrates (High risk): CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates (High risk).
Management
Monitor therapy

Subscribe for latest updates

Subscribe to our e-mail newsletter to receive updates.

No comments yet.

Post Review about Rosiglitazone and metformin vs CYP2C8 Substrates (High risk)


Other Interactions of Rosiglitazone and metformin

We are Developing Our database, More results coming soon.